A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs ACE 083 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions
- Sponsors Acceleron Pharma
- 28 Feb 2018 According to an Acceleron Pharma media release, results of second part of the trial are expected in the second half of 2019.
- 27 Feb 2018 Planned number of patients changed from 76 to 92.
- 27 Feb 2018 Planned End Date changed from 1 Apr 2019 to 1 May 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History